HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain

Biochimica et Biophysica Acta - Biomembranes

Volumn 1818, Issue 12, 2012, Pages 2950-2957

  Lu, Lu ^a,c   Tong, Pei ^b   Yu, Xiaowen ^b,c   Pan, Chungen ^c,d   Zou, Peng ^c   Chen, Ying Hua ^b   Jiang, Shibo ^a,c  

^a FUDAN UNIVERSITY   (China)

^b Tsinghua University   (China)

^c NEW YORK BLOOD CENTER   (United States)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Drug resistance; Fusion inhibitors; gp41; HIV 1; Membrane binding; Mutation

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C34 PEPTIDE; ENFUVIRTIDE; GLYCOPROTEIN GP 41; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENCY; DRUG POTENTIATION; DRUG STABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMBRANE BINDING; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS ATTACHMENT; VIRUS FUSION; VIRUS MUTATION; WILD TYPE;

CELL LINE; GENETIC VARIATION; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MEMBRANE MICRODOMAINS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; POINT MUTATION; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84865335285     PISSN: 00052736     EISSN: 18792642     Source Type: Journal    
DOI: 10.1016/j.bbamem.2012.07.020     Document Type: Article

References (55)

1. R. Wyatt, and J.G. Sodroski The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens Science 280 1998 1884 1888
2. R. Brasseur, B. Cornet, A. Burny, M. Vandenbranden, and J.M. Ruysschaert Mode of insertion into a lipid membrane of the N-terminal HIV gp41 peptide segment AIDS Res. Hum. Retroviruses 4 1988 83 90
3. Y. He, R. Vassell, M. Zaitseva, N. Nguyen, Z. Yang, Y. Weng, and C.D. Weiss Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites J. Virol. 77 2003 1666 1671
4. Y. Kliger, A. Aharoni, D. Rapaport, P. Jones, R. Blumenthal, and Y. Shai Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell fusion - structure-function study J. Biol. Chem. 272 1997 13496 13505
5. K. Tan, J. Liu, J. Wang, S. Shen, and M. Liu Atomic structure of a thermostable subdomain of HIV-1 gp41 Proc. Natl. Acad. Sci. U. S. A. 94 1997 12303 12308
6. D.C. Chan, D. Fass, J.M. Berger, and P.S. Kim Core structure of gp41 from the HIV envelope glycoprotein Cell 89 1997 263 273
7. W. Weissenhorn, A. Dessen, S.C. Harrison, J.J. Skehel, and D.C. Wiley Atomic structure of the ectodomain from HIV-1 gp41 Nature 387 1997 426 428
8. R. Furuta, C.T. Wild, Y. Weng, and C.D. Weiss Capture of an early fusion-active comformation of HIV-1 gp41 Nat. Struct. Biol. 5 1998 276 279
9. Y. Kliger, and Y. Shai Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation J. Mol. Biol. 295 2000 163 168
10. S. Jiang, K. Lin, N. Strick, and A.R. Neurath Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41 Biochem. Biophys. Res. Commun. 195 1993 533 538
11. S. Jiang, K. Lin, N. Strick, and A.R. Neurath HIV-1 inhibition by a peptide Nature 365 1993 113
12. C. Wild, J.W. Dubay, T. Greenwell, T. Baird Jr., T.G. Oas, C. McDanal, E. Hunter, and T. Matthews Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex Proc. Natl. Acad. Sci. U. S. A. 91 1994 12676 12680
13. C. Wild, T. Greenwell, and T. Matthews A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion AIDS Res. Hum. Retroviruses 9 1993 1051 1053
14. M. Lu, and P.S. Kim A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein J. Biomol. Struct. Dyn. 15 1997 465 471
15. C. Wild, T. Oas, C. McDanal, D. Bolognesi, and T. Matthews A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition Proc. Natl. Acad. Sci. U. S. A. 89 1992 10537 10541
16. J.J. Dwyer, A. Hasan, K.L. Wilson, J.M. White, T.J. Matthews, and M.K. Delmedico The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation Biochemistry 42 2003 4945 4953
17. M. Gochin The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket J. Med. Chem. 2009 4338 4344
18. D.C. Chan, C.T. Chutkowski, and P.S. Kim Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target Proc. Natl. Acad. Sci. U. S. A. 95 1998 15613 15617
19. H. Ji, W. Shu, T. Burling, S. Jiang, and M. Lu Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion J. Virol. 73 1999 8578 8586
20. Z. Qi, W. Shi, N. Xue, C. Pan, W. Jing, K. Liu, and S. Jiang Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors J. Biol. Chem. 283 2008 30376 30384
21. S. Liu, W. Jing, B. Cheung, H. Lu, J. Sun, X. Yan, J. Niu, J. Farmar, S. Wu, and S. Jiang HIV gp41 C-terminal heptad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides J. Biol. Chem. 282 2007 9612 9620
22. S. Liu, H. Lu, Y. Xu, S. Wu, and S. Jiang Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120 J. Biol. Chem. 280 2005 11259 11273
23. D.A. Cooper, and J.M. Lange Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development Lancet Infect. Dis. 4 2004 426 436
24. J.M. Kilby, and J.J. Eron Novel therapies based on mechanisms of HIV-1 cell entry, N.Engl J. Med. 348 2003 2228 2238
25. X. Wei, J.M. Decker, H. Liu, Z. Zhang, R.B. Arani, J.M. Kilby, M.S. Saag, X. Wu, G.M. Shaw, and J.C. Kappes Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob. Agents Chemother. 46 2002 1896 1905
26. M. Mink, S.M. Mosier, S. Janumpalli, D. Davison, L. Jin, T. Melby, P. Sista, J. Erickson, D. Lambert, S.A. Stanfield-Oakley, M. Salgo, N. Cammack, T. Matthews, and M.L. Greenberg Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro J. Virol. 79 2005 12447 12454
27. D. Eggink, C.E. Baldwin, Y. Deng, J.P. Langedijk, M. Lu, R.W. Sanders, and B. Berkhout Selection of T1249-resistant human immunodeficiency virus type 1 variants J. Virol. 82 2008 6678 6688
28. L.T. Rimsky, D.C. Shugars, and T.J. Matthews Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides J. Virol. 72 1998 986 993
29. N. Ray, L.A. Blackburn, and R.W. Doms HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide J. Virol. 83 2009 2989 2995
30. N. Ray, J.E. Harrison, L.A. Blackburn, J.N. Martin, S.G. Deeks, and R.W. Doms Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors J. Virol. 81 2007 3240 3250
31. M. Armand-Ugon, A. Gutierrez, B. Clotet, and J.A. Este HIV-1 resistance to the gp41-dependent fusion inhibitor C-34 Antiviral Res. 59 2003 137 142
32. S.G. Peisajovich, S.A. Gallo, R. Blumenthal, and Y. Shai C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIV-induced membrane fusion J. Biol. Chem. 278 2003 21012 21017
33. Y. Kliger, S.A. Gallo, S.G. Peisajovich, I. Munoz-Barroso, S. Avkin, R. Blumenthal, and Y. Shai Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage J. Biol. Chem. 276 2001 1391 1397
34. H. Edelhoch Spectroscopic determination of tryptophan and tyrosine in proteins Biochemistry 6 1967 1948 1954
35. Y. Weng, Z. Yang, and C.D. Weiss Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41 J. Virol. 74 2000 5368 5372
36. E. Desmezieres, N. Gupta, R. Vassell, Y. He, K. Peden, L. Sirota, Z. Yang, P. Wingfield, and C.D. Weiss Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120 J. Virol. 79 2005 4774 4781
37. X. Yu, L. Lu, L. Cai, P. Tong, S. Tan, P. Zou, F. Meng, Y.H. Chen, and S. Jiang Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket J. Virol. 86 2012 589 593
38. W. Shu, J. Liu, H. Ji, L. Radigan, S. Jiang, and M. Lu Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides Biochemistry 39 2000 1634 1642
39. S. Liu, Q. Zhao, and S. Jiang Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors Peptide 24 2003 1303 1313
40. S. Jiang, H. Lu, S. Liu, Q. Zhao, Y. He, and A.K. Debnath N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion Antimicrob. Agents Chemother. 48 2004 4349 4359
41. L. Li, L. He, S. Tan, X. Guo, H. Lu, Z. Qi, C. Pan, X. An, S. Jiang, and S. Liu 3-Hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1 Antimicrob. Agents Chemother. 54 2010 1700 1711
42. C. Pan, L. Cai, H. Lu, Z. Qi, and S. Jiang Combinations of the first and next generation HIV fusion inhibitors exhibit highly potent synergistic effect against enfuvirtide-sensitive and resistant HIV-1 strains J. Virol. 83 2009 7862 7872
43. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
44. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
45. Y. Weng, and C.D. Weiss Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41 J. Virol. 72 1998 9676 9682
46. H. Ji, W. Shu, T. Burling, S. Jiang, and M. Lu Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion J. Virol. 73 1999 8578 8586
47. J.M. Kilby, J.P. Lalezari, J.J. Eron, M. Carlson, C. Cohen, R.C. Arduino, J.C. Goodgame, J.E. Gallant, P. Volberding, R.L. Murphy, F. Valentine, M.S. Saag, E.L. Nelson, P.R. Sista, and A. Dusek The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults AIDS Res. Hum. Retroviruses 18 2002 685 693
48. J.M. Kilby, S. Hopkins, T.M. Venetta, B. DiMassimo, G.A. Cloud, J.Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M.R. Johnson, M.A. Nowak, G.M. Shaw, and M.S. Saag Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry Nat. Med. 4 1998 1302 1307
49. C. Wild, T. Greenwell, D. Shugars, L. Rimsky-Clarke, and T. Matthews The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure AIDS Res. Hum. Retroviruses 11 1995 323 325
50. J.J. Dwyer, K.L. Wilson, D.K. Davison, S.A. Freel, J.E. Seedorff, S.A. Wring, N.A. Tvermoes, T.J. Matthews, M.L. Greenberg, and M.K. Delmedico Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus Proc. Natl. Acad. Sci. U. S. A. 104 2007 12772 12777
51. Z. Liu, M. Shan, L. Li, L. Lu, S. Meng, C. Chen, Y. He, S. Jiang, and L. Zhang In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor J. Biol. Chem. 286 2010 3277 3287
52. D. Eggink, I. Bontjer, J.P. Langedijk, B. Berkhout, and R.W. Sanders Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function J. Virol. 85 2011 10785 10797
53. B. Berkhout, D. Eggink, and R.W. Sanders Is there a future for antiviral fusion inhibitors? Curr. Opin. Virol. 2 2012 50 59
54. D.D. Ho Therapy of HIV infections: problems and prospects Bull. N. Y. Acad. Med. 73 1996 37 45
55. C. Pan, H. Lu, Z. Qi, and S. Jiang Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors AIDS 23 2009 639 641